Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
| Autor: | Seung-Mi Lee, Emmett R Henderson, Scott K. Griggs, Taehwan Park, Dong-Churl Suh |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Statin Cost effectiveness medicine.drug_class Atorvastatin Cost-Benefit Analysis Hypercholesterolemia 030204 cardiovascular system & hematology Placebo Drug Costs 03 medical and health sciences 0302 clinical medicine Ezetimibe Internal medicine medicine Humans Pharmacology (medical) Rosuvastatin cardiovascular diseases 030212 general & internal medicine health care economics and organizations business.industry Health Policy PCSK9 Anticholesteremic Agents PCSK9 Inhibitors nutritional and metabolic diseases General Medicine Treatment Outcome Simvastatin Cardiovascular Diseases lipids (amino acids peptides and proteins) Drug Therapy Combination Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Expert review of pharmacoeconomicsoutcomes research. 18(1) |
| ISSN: | 1744-8379 |
| Popis: | The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new treatment option for patients with hypercholesterolemia. The objective of this study was to systematically review the cost-effectiveness of lipid-lowering agents.Based on Pubmed, Embase, and Cochrane Database of Systematic Reviews, we identified 29 relevant articles. Studies found statins were cost-effective compared with placebo or no treatment in general. Atorvastatin was reported to be cost-effective against simvastatin. In most cases, rosuvastatin was more cost-effective than atorvastatin or simvastatin. Additionally, ezetimibe was considered to be cost-effective compared with no treatment for statin intolerant patients. For patients not meeting treatment goals with their statins, switching to ezetimibe plus simvastatin was consistently reported cost-effective. The cost-effectiveness of ezetimibe plus a hybrid of a statin varied by the source of clinical data and cost of ezetimibe. Finally, the cost-effectiveness of PCSK9 inhibitor plus a statin against statin monotherapy was uncertain. The PCSK9 inhibitor plus a stain was cost-ineffective compared with ezetimibe plus a statin.Drug costs and treatment efficacy were the key drivers of the cost-effectiveness results in prior analyses. Future evaluations are warranted to reflect the decreasing drug prices and the long-term treatment effects of PCSK9 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|